XML 53 R30.htm IDEA: XBRL DOCUMENT v3.22.4

Revenue (Tables)

12 Months Ended

Dec. 31, 2022

Revenue [abstract]

Schedule of Revenue Recognized in Consolidated Statement of Profit or Loss

Revenue has been recognized in the consolidated statements of profit or loss with the following amounts:

		2022				2021				2020
		(EUR’000)
Revenue
Commercial sale of products			35,659				943				—
Rendering of services			4,434				751				2,140
Sale of clinical supply			8,534				3,719				2,206
Licenses			2,547				2,365				2,607
Total revenue			51,174				7,778				6,953
Attributable to
Commercial customers			35,659				943				—
Collaboration partners and license agreements			15,515				6,835				6,953
Total revenue			51,174				7,778				6,953
Specified by timing of recognition
Recognized over time			4,434				751				2,140
Recognized at a point in time			46,740				7,027				4,813
Total revenue			51,174				7,778				6,953
Specified per geographical location
Europe			552				—				—
North America			44,156				6,856				2,679
China			6,466				922				4,274
Total revenue			51,174				7,778				6,953

X

- Definition

Disclosure of segment revenues by destination of major customers explanatory.

+ References

No definition available.

+ Details

Name:	asnd_DisclosureOfSegmentRevenuesByDestinationOfMajorCustomersExplanatory
Namespace Prefix:	asnd_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	ifrs-full_RevenueAbstract
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration